Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon + NAs for HCC Prevention in HBV
NCT05721300Unknown
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Randomised, open-label trial in Chronic Hepatitis B (CHB) (2 arms), sponsored by Zhongshan Hospital (Xiamen), Fudan University. Primary endpoint: Incidence of early liver cancer. Status: unknown.
02
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05721300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05721300.